– UK, Road Town – Fragrant Prosperity Holdings Limited (LON: FPP) today announced the appointment of Dr. Daniel S. Reshef, MD, MPH, Ph.D. to its Board of Directors as a non-executive director, effective as of March 31, 2021.
“I have personally known and worked with Dr. Daniel Reshef for well over 7 years, and have always been impressed with his world wide experience and skill set. I am delighted to welcome him to the Board and look forward to the additional expertise that he brings to the Company” said Board Chairman, Craig Marshak.
The company is seeking an acquisition in several sectors but is currently focused on Cannabis Therapeutics.
About Dr. Daniel Reshef
Dr. Daniel Reshef is a dual Israeli and USA Citizen, currently living in the USA, with strong ties to Israel, Israel medical research centers, and a vast array of relationships in the global pharmaceutical sector.
Dr. Reshef’s extensive career with over twenty-five years in drug development encompasses many facets of the Pharmaceutical sector, gained through senior management positions at leading companies such as Hoffman La Roche, Genentech, Bristol Myers Squibb, and in his current capacity as the Therapeutic Area Global Head for a major global Pharmaceutical Company. His scientific experience includes skills in regulatory, medical affairs, drug safety operations, and clinical trial epidemiology with leadership experience in early drug development from phase 1 to phase IV and in multiple therapeutic areas.
Dr. Reshef is a board-certified physician, a graduate of the Hebrew University and Hadassah Medical School in Jerusalem, and has earned his MPH and Ph.D. in Epidemiology from Johns Hopkins University.
For more information: http://www.fragrantprosperityholdings.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.